4.1 Therapeutic indications
Doxycycline has been found clinically effective in the treatment of a variety of infectionscaused by susceptible strains of Gram-positive and Gram-negative bacteria and certain other micro-organisms.
Pneumonia and other lower respiratory tract infections due to susceptible strains of Streptococcus pneumoniae, Haemophilusinfluenzae, Klebsiella pneumoniae and other organisms. Mycoplasma pneumoniae pneumonia. Treatment of chronic bronchitis, sinusitis.
Infections caused by susceptible strains of Klebsiella species, Enterobacter species. Escherichia coli, Streptococcus faecalis and otherorganisms.
Infections due to Chlamydia trachomatis including uncomplicated urethral, endocervical or rectal infections. Non-gonococcal urethritis caused by Ureaplasma urealyticum (T-mycoplasma). Doxycycline is also indicated in chancroid, granuloma inguinale and lymphogranuloma venereum. Doxycycline is an alternative drug in the treatment of gonorrhoea andsyphilis.
Acne vulgaris when antibiotic therapy is considerednecessary.
Since Doxycycline is a member of the tetracycline group of antibiotics, it may be expected to be useful in the treatment of infections which respond to other tetracyclines suchas:
Due to susceptible strains of gonococci, staphylococci and Haemophilusinfluenzae. Doxycycline Capsules are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged byimmunofluorescence. Inclusion conjunctivitis may be treated with oral Doxycycline alone or in combination with topical agents.
Rocky Mountain spotted fever, typhus group, Q fever, Coxiella endocarditis and tickfevers.
Psittacosis, cholera, bubonic plague, meliodosis, leptospirosis, other infections due to susceptible strains of Yersinia species, tularaemiaglanders, Brucella species (in combination with Streptomycin), Clostridiumspecies, Francisellatularensis and chloroquine-resistant falciparummalaria and acute intestinal amoebiasis (as an adjunct to amoebicides).
Doxycycline Capsules are indicated for prophylaxis in the following conditions: Scrub typhus, traveller's diarrhoea (enterotoxigenic Escherichia coli),leptospirosis.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.
Medthority will not be held liable for explicit or implicit errors, or missing data.
Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).